Head-to-head Comparison of Perfluorobutane Contrast-Enhanced US and Multiparametric MRI for Breast Cancer: a Prospective, Multicenter Study
Manlin Lang,Ping Liang,Haibo Shen,Hang Li,Ning Yang,Bin Chen,Yixu Chen,Hong Ding,Weiping Yang,Xiaohui Ji,Ping Zhou,Ligang Cui,Jiandong Wang,Weihua Xu,Xiuqin Ye,Zhixing Liu,Yang Yu,Tianci Wei,Hui Wang,Yuanyuan Yan,Changjun Wu,Yiyun Wu,Jingwen Shi,Yaxi Wang,Xiuxia Fang,Ran li,Jie Yu
DOI: https://doi.org/10.21203/rs.3.rs-2191087/v1
2022-01-01
Abstract:Background: Multiparametric - Magnetic Resonance Imaging (MP-MRI) has high sensitivity for diagnosing breast cancers but cannot always be used as a routine diagnostic tool. To evaluate whether the diagnostic performance of Perfluorobutane (PFB)-contrast enhanced ultrasound (CEUS) is like MP-MRI in the breast cancer and if combining the two methods would enhance diagnostic efficiency. Patients and Methods: This was a head-to-head, prospective, multicenter study. Patients with breast lesions diagnosed by US as Breast Imaging Reporting and Data System (BI-RADS) 3, 4, and 5 categories underwent both PFB-CEUS and MP-MRI scans. On-site operators and three reviewers categorized the BI-RADS of all lesions on two images, respectively. Logistic-bootstrap 1000-sample analysis and cross-validation were used to construct PFB-CEUS, MP-MRI, and hybrid (PFB-CEUS + MP-MRI) models to distinguish breast lesions. Results : In total, 179 women with 186 breast lesions were evaluated from 17 centers in China. The area under the receiver operating characteristic curve (AUC) for the PFB-CEUS model (0.89; 95% confidence interval [CI]: 0.74, 0.97) was like that of the MP-MRI model (0.89; 95% CI: 0.73, 0.97), whereas both were inferior to the hybrid model (0.92, 95% CI: 0.77, 0.98). 90.3% false-positive and 66.7% false-negative results of PFB-CEUS radiologists, 90.5% false-positive and 42.8% false-negative results of MP-MRI radiologists could be corrected by Hybrid model, respectively. Dynamic nomograms of three models are accessible on websites. Conclusions : PFB-CEUS can be used in differential diagnosis of breast cancer with the performance comparable to MP-MRI. Using PFB-CEUS and MP-MRI as joint diagnostics could further strengthen the diagnostic ability. Trial registration : Clinicaltrials.gov; NCT04657328. Registered 26 September 2020.